Apellis Pharmaceuticals, INC Schedule 13G passive stakes

Morgan Stanley has filed an amendment to its Schedule 13G, reporting that it no longer beneficially owns more than five percent of Apellis Pharmaceuticals common stock.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 4,532,374 shares, representing 3.55% of the outstanding common stock of Apellis Pharmaceuticals, Inc. as of March 31, 2026.

RTW Investments, LP and Roderick Wong report beneficial ownership of 3,685,045 shares, representing 2.9% of Apellis Pharmaceuticals, Inc. common stock.

State Street Corporation has reported beneficial ownership of 5.4% of Apellis Pharmaceuticals Inc. common stock as of March 31, 2026.

Wellington Management Group has reduced its stake in Apellis Pharmaceuticals to 0.2%, signaling a significant divestment by the institutional giant.

The Vanguard Group reported a 0% beneficial ownership in Apellis Pharmaceuticals Inc. common stock following an internal corporate realignment.

RTW Investments, LP and Managing Partner Roderick Wong, M.D. have disclosed a 6.1% beneficial ownership stake in Apellis Pharmaceuticals, Inc.

BlackRock, Inc. has reported a significant beneficial ownership stake of 10.5% in Apellis Pharmaceuticals Inc. common stock.

EcoR1 Capital, LLC and related entities filed an amended Schedule 13G, disclosing a 2.7% beneficial ownership stake in Apellis Pharmaceuticals, Inc. as of September 30, 2025.

Wellington Management Group and its affiliates reported an increased beneficial ownership of 10.87% in Apellis Pharmaceuticals, Inc., holding 13,750,547 common shares.

Wellington Management Group and its affiliates have reported a 7.17% beneficial ownership stake in Apellis Pharmaceuticals, Inc. as of June 30, 2025.

Deep Track Capital, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.57% in Apellis Pharmaceuticals, Inc., totaling 7,000,000 shares.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.5% passive ownership stake in Apellis Pharmaceuticals, Inc. as of March 31, 2025.

Wellington Management Group LLP and its affiliates have reported a continued beneficial ownership of 9.5% of Apellis Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Morgan Stanley and its subsidiary have filed a Schedule 13G, revealing beneficial ownership of 7.7% of Apellis Pharmaceuticals, Inc.'s common stock.